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White matter hyperintensities (WMH) are lesions in 
the brain that show up as areas of increased 
brightness when visualised by T2-weighted or fluid-
attenuated inversion recovery (FLAIR) magnetic 
resonance imaging (MRI). WMH commonly form in 
normal aging, increasing in prevalence from 11-21 
percent at 64 years of age to 94 percent at 82 years 
of age.1,2 They are more common in those with small 
vessel disease and cardiovascular risk factors, and 
they display heritability of up to 76 percent.3 
Pathologically, WMH represent local oedema, often 
secondary to demyelination and axonal loss. Based 
on aetiology and region, they can be subdivided into 
two distinct types: deep (DWMH) and periventricular 
(PWMH). DWMH occur in subcortical areas and are 
typically associated with small vessel disease.4 
PWMH occur in ependymal areas and are believed to 
be caused by ventricular cerebrospinal fluid (CSF) 
pulsations leading to microtears in the ependymal 
lining.5 In normal aging, WMH predominantly affect 
the frontal lobe, whereas diffuse WMH tend to 
indicate other aetiologies.6,7 
WMH are important markers of loss of cerebral 
integrity. They are significantly associated with 
increased stroke risk, cognitive decline (globally as 
well as in the domains of executive function and 
processing speed), dementia, and mortality.8 Thus, 
as a non-invasive clinical test, they may be useful in 
prompting detailed screening for cardiovascular risk 
factors. In research, they may be a useful 
intermediate marker to test the efficacy of novel 
preventative therapies. 
Recently, WMH have been found at a greater 
incidence in high-altitude U-2 pilots. Here we discuss 
these findings and hypothesise that, given the 
similarities between U-2 flight and extravehicular 
activities (EVAs) operating conditions, WMH is a 
phenomenon that may be relevant to the future 
astronauts of exploration missions that are currently 
being planned. 
 
WMH IN HIGH-ALTITUDE PILOTS 
In 2013, McGuire et al. discovered a greater 
incidence of DWMH in high-altitude U-2 pilots 
compared to healthy controls.9 This finding was 
present even in U-2 pilots who had not suffered from 
clinical neurological decompression sickness (DCS). 
A subsequent study confirmed the same finding in 
hypobaric chamber personnel, providing strong 
evidence that the WMH are related to hypobaric 
exposure, rather than other potentially confounding 
aviation-related factors like hypoxia, high sustained 
positive acceleration, radiation, or use of stimulant 
drugs.10 
The volume of WMH lesions was greater in U-2 pilots 
who had experienced neurological DCS, suggesting 
that the two may be pathologically related.11 In 
contrast to the predominantly frontal WMH in healthy 
controls, the WMH in pilots were uniformly distributed 
throughout the brain in subcortical areas. This is 
consistent with the aetiological hypothesis of a diffuse 
process such as thrombosis, coagulation, and/or 
inflammation, secondary to microembolic nitrogen 
gas bubbles formed during hypobaric exposure. A 
study of fractional anisotropy in this cohort 
demonstrated diffuse white matter damage beyond 
the punctate damage implied by WMH, adding weight 
to this hypothesis.12 
WMH in U-2 pilots were found to be associated with 
subclinical neurocognitive decline, specifically in the 
domains of reasoning/calculation, memory, 
information processing accuracy, and general 
cognitive functioning.13 The natural history (i.e. 
reversibility versus progression) and long-term 
consequences of hypobaria-induced WMH remain 
unknown, so further follow-up of this cohort is strongly 
recommended. Given their distinct underlying 
pathological process, it is difficult to predict if 
hypobaria-induced WMH display the familiar 
associations of stroke, progressive cognitive decline, 




U-2 OPERATING CONDITIONS 
The U-2 high-altitude reconnaissance aircraft is 
operated by the United States Air Force above 21,000 
m (70,000 ft).14 Prior to 2014, cabin altitude was 
maintained at approximately 9,000 m (30,000 ft), 
equivalent to 30.3 kPa (4.4 psia). The cohort of pilots 
studied by McGuire et al. were exposed to these 
hypobaric conditions for up to nine hours at a time, no 
more often than every third day.10 Hypobaric chamber 
technicians were exposed to similar altitudes at 
similar frequencies, but with durations of only 30 to 60 
minutes. 
In order to mitigate DCS risk, U-2 pilots undergo a 
pre-breathe (PB) of 100% O2 for one hour prior to 
take-off. U-2 pilots may also exercise during oxygen 
prebreathing to increase the efficiency of nitrogen 
washout.15 The pilots are maintained on 100% O2 for 
the duration of the flight, which ensures normal 
arterial oxygenation and ongoing protection from 
DCS.16 
In 2014 the Cockpit Altitude Reduction Effort (CARE) 
drove aircraft modifications to increase cabin 
pressure to 57.9 kPa (8.4 psia), a 4,450 m (14,600 ft) 
altitude equivalent.17,18 This was deemed necessary 
due to increasing DCS incidence in the preceding 
decade, presumed to be secondary to increasing 
mission frequency and duration. Since the 
implementation of Project CARE, there have been no 
further cases of DCS in U-2 pilots reported publicly. 
WMH have not been investigated in newer U-2 pilots 
who have only been exposed to these higher 
pressures. 
WMH IN ASTRONAUTS 
EVA Operating Conditions 
Astronauts performing an EVA are exposed to 
hypobaric conditions similar to those for U-2 pilots 
(Table 1). An EVA is undertaken in a gas-pressure 
suit, of which two models are currently in use: the 
NASA Extravehicular Mobility Unit (EMU) and the 
Russian Orlan spacesuit. These suits operate at 29.6 
kPa (4.3 psia) and 40 kPa (5.8 psia) respectively, 
subjecting astronauts to significant decompression 
from the 101.4 kPa (14.7 psia) Earth-normal 
atmosphere on the International Space Station (ISS) 
(pressure delta 71.7 kPa [10.4 psia] and 61.4 kPa [8.9 
psia] respectively).19 Such low operating pressures 
are used in EVA suits because with current suit 
design, higher pressures cause fatigue, reduced 
mobility and dexterity, and increased risk of injury. 
Hypobaria duration is similar to U-2 pilots, with an 
EVA typically lasting for around 4 to 8 hours. The 
longest EVA on record is 8 hours and 56 minutes.20 
These operating conditions result in a high risk of 
DCS. Like for U-2 pilots, this risk is mitigated with PB 
techniques that aim to achieve adequate 
denitrogenation prior to decompression. The primary 
protocol in use on the ISS is the in-suit light exercise 
(ISLE) protocol, which involves a 190-minute PB of 
100% O2, including 50 minutes of mild in-suit 
exercise.19 Other available protocols include a simple 
in-suit 4-hour PB of 100% O2, and the campout 
protocol, in which the two EVA crewmembers sleep in 
the ISS airlock at reduced pressure during the night 
prior to EVA in order to reduce the in-suit PB duration. 
DCS Incidence in Astronauts 
No DCS has been reported in astronauts undertaking 
EVAs using any of these PB protocols.19 However, a 
discrepancy exists between operational and research 
reports, in that research subjects evaluating the same 
PB protocols in hypobaric chambers report about 
20% DCS.21 Various reporting factors may be 
responsible for this disagreement, including DCS 
symptom under-reporting, masking by spacesuit-
related symptoms, premedication with anti-
inflammatories, and mild symptom severity and 
progression unconducive to reporting. Additionally, 
factors related to the spaceflight environment may 
truly reduce the incidence of DCS in orbit. The most 
prominent of these is the lack of lower limb motion 
during EVA which likely limits DCS and venous gas 
embolism (VGE) from the lower body. More 
conservative PB performed in space may also 
contribute. Anatomical and physiological changes in 
microgravity may result in more efficient 
denitrogenation, and various other operational factors 
related to the in-suit atmosphere composition and 
temperature may be significant.  
Ultimately, the effect of the spaceflight environment 
on denitrogenation efficacy and DCS incidence is 
unknown. 
WMH Incidence in Astronauts 
Given the aforementioned similarities between the 
parameters of EVA and U-2 operations (pressure 
delta and hypobaria duration), it is reasonable to 
wonder whether WMH may also be occurring in 
astronauts. Indeed, an initial study found an 
increased incidence of WMH in twenty-one 
astronauts at even greater levels than in U-2 pilots.22 
However, there was no significant difference between 
WMH burden in EVA and non-EVA astronauts, 
suggesting that hypobaria is not the primary driver of 
WMH in this population. A subsequent study clarified 
that astronauts tend to have increased PWMH but no 
increased DWMH.23 This is likely related to unique 
characteristics of the spaceflight environment such as 
cephalad fluid shift in microgravity increasing 
hydrostatic pressure from CSF into brain 
parenchyma, and shear forces from launch vibration 
disrupting the CSF-brain interface.  
The PWMH were associated with increased 
ventricular CSF volume and demonstrated partial  
reversibility at one month. In contrast, the absence of 
increased DWMH in EVA astronauts, despite the 
exposure similarities with U-2 pilots, suggests the 
presence of protective factors. 
One possible explanation for the lack of DWMH 
findings in astronauts could be the significantly 
reduced frequency at which EVAs are undertaken, 
compared to that of flying in the U-2 pilot cohort. 
Historically, any individual astronaut will perform an 
EVA at most four times per year, usually with weeks 
or months elapsing between each occasion (though 
some astronauts have performed multiple EVAs 
within the space of a week).20 While McGuire et al. 
found no correlation between the DWMH burden and 
number of flight hours in the U-2 pilot cohort, it could 
be that there is a minimum threshold of hypobaric 
exposure frequency that is required for DWMH to 
develop in the first instance, which current astronauts 
have not exceeded.9 
Furthermore, the same factors which are 
hypothesized to be responsible for the lack of DCS in 
astronauts could also play a role in reducing DWMH 
incidence. More extensive PB protocols and the 
various factors related to the spaceflight environment 
discussed previously could be resulting in less 
stressful hypobaric exposures than in the U-2 pilot 
cohort, protecting astronauts from DWMH 
development. 
Implications for Future Space Operations 
Future space operations will introduce largely 
different operating conditions for astronauts, so that 
despite the absence of DWMH found in the current 
astronaut population, the relevance of DWMH must 
still be considered. Most notably, future surface 
exploration missions (i.e. to the Moon and Mars) will 
likely require significantly increased EVA frequency, 
up to multiple times per person per day. In order for 
this to be logistically feasible while meeting 
acceptable DCS risk, significantly altered spacecraft, 
habitat, in-suit atmospheres, and PB protocols will be 
required. 
The basis of future EVA architecture development is 
an 56.5 kPa (8.2 psia) / 34% O2 Exploration 
Atmosphere, which has been selected as a 
compromise to reduce the pressure delta for EVA, 
while maintaining astronaut oxygenation status and 
acceptable fire risk.24 This would be combined with 
the use of a variable pressure EVA suit and suitports 
to allow for highly efficient donning and doffing 
procedures.25 The suit would be decompressed to 
29.6 kPa (4.3 psia) for most of the EVA duration, 
although more work is being done to quantify the 
human health and performance impacts of using 
higher suit pressures. Model predictions suggest that 
a 15-minute O2 PB protocol would be sufficient to 
maintain DCS risk below currently acceptable 
levels.25 Furthermore, performing multiple EVAs per 
day would result in intermittent recompression, which 
has been shown to reduce decompression stress 
under some circumstances.26 
While the use of the Exploration Atmosphere does 
significantly reduce pressure delta (26.9 kPa [3.9 
psia]), all other factors make these operating 
conditions more comparable with U-2 flying than are 
ISS EVAs (see Table 1). EVA duration will likely 
remain equivalent, but EVA frequency and cumulative 
hours could exceed those of U-2 pilots. Furthermore, 
unlike ISS EVAs, exploration EVAs will involve gravity 
and lower limb movement. Taken together, these 
operational similarities warrant concern about the 
relevance of DWMH to future astronauts. 
 
Table 1: Comparison of operating conditions for U-2 
aircraft, ISS EVA, and proposed exploration EVA. 
 
 
Mechanical Counterpressure (MCP) Suits 
MCP suits are an emerging alternative to traditional 
gas-pressure suits. They work by application of 
mechanical pressure directly to the skin, rather the 
maintenance of an atmosphere surrounding the skin. 
The technology is in development at MIT, called the 
BioSuit, but it is considered to be a long-term project 
with no foreseeable completion date. The BioSuit 
aims to uniformly apply 30.3 kPa (4.4 psia) to all body 
surfaces, except for the head and the hands which will 
be contained within gas-pressure enclosures.27 While 
this does seem to be a promising solution for mobility 
and aesthetics, there is no obvious benefit in terms of 
the pressure delta to which astronauts will be 
subjected. Furthermore, the technology may be 
imperfect, resulting in localized areas of under- or 
over-pressure. The effects that this may have on DCS 
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and WMH risk are unknown. Speculatively it seems 
that even small areas of under-pressure could 
precipitate local nitrogen bubble formation, and areas 
of over-pressure could perhaps impair nitrogen 
washout. Therefore, even with MCP suits on the 
distant horizon, it seems that further work regarding 
DWMH is justified. 
Knowledge Gaps 
In order to confidently understand the relevance of 
DWMH to the current and future astronaut population, 
more knowledge about their pathophysiology, 
incidence, and long-term consequences is required. 
More understanding of the pathophysiology behind 
DWMH is necessary to model risk for future EVA 
architectures. McGuire et al. suggest that an animal 
model could be developed to better understand the 
responsible mechanisms.10 In humans, the link 
between VGE and DCS has been well studied, and 
although the exact nature of the relationship remains 
unclear, VGE appears to have high negative 
predictive value (i.e. the absence of VGE predicts that 
DCS will not occur).28 However, this relationship does 
not appear to hold for neurological DCS, and the link 
between VGE and WMH has not been studied.29 
Therefore, prospectively monitoring VGE incidence in 
U-2 pilots or hypobaric chamber technicians with 
respect to the development of WMH could enhance 
pathophysiological understanding. If an association 
was to be found, then VGE may have potential as an 
intermediate marker for further DWMH research, 
especially on astronauts. 
Learning more details about the incidence of DWMH 
in different groups exposed to hypobaria may also 
shed some light on its pathophysiology. For example, 
patent foramen ovale (PFO) is present in about 25% 
of the general population and can result in cerebral 
arterial gas embolism, but has not been analysed for 
its effect on DWMH incidence.30 Further studies on U-
2 pilots that only started training after the 
implementation of CARE in 2014 would be of interest 
to understand the effect of a smaller pressure delta, 
closer to those being proposed for future EVA 
architectures. If DWMH incidence remains elevated, 
prospectively following a cohort of new U-2 pilots, or 
new hypobaric chamber technicians, could reveal 
how much hypobaric exposure is required before 
DWMH develop. 
Long-term MRI surveillance should be performed on 
the current and future astronaut population to see if 
DWMH or other imaging changes develop exclusively 
to those who have undertaken EVA. Long-term 
clinical monitoring of U-2 pilots with and without 
DWMH will be essential to understand the potential 
implications for future astronauts. If the disease 
associations did turn out to be similar to those of 
WMH in the general population (stroke, cognitive 
decline, death), the consequences for a long-term 
space colony could be potentially devastating. 
Conclusion 
WMH are important markers of loss of cerebral 
integrity and have significant disease associations in 
the general population. Hypobaria-induced WMH 
likely indicate subclinical decompression stress 
although the mechanisms of their formation are still 
unclear. While they have not been observed in 
astronauts under current EVA operating conditions, 
they should be considered in the context of future 
mission planning. More work is required to 
understand why they occur, their relevance to 
astronauts, and what the long-term implications may 
be. 
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